Loading clinical trials...

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT04868968

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.

Lead sponsor: Novartis Pharmaceuticals•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 3

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

NCT00991146 · Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, and more

COMPLETEDPhase 3

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373 · Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 9, 2024Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment4

Start dateSep 2021

Last updatedOct 9, 2024

Condition

Familial Cold Autoinflammatory Syndrome

Locations shown

Novartis Investigative Site

La Jolla, California

Novartis Investigative Site

Paris

Novartis Investigative Site

Tübingen

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 9, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Trial snapshot

Condition

Locations shown

For caregivers